Why most (but perhaps not all) DMARDs work equally well
Seminars in Arthritis and Rheumatism, vol. 64, pp. 152316
Abstract
Biological- or targeted-synthetic DMARD-responses reported in randomized clinical trials, placebo-controlled or head-to-head, in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis are unbelievably similar, when looking across trials performed in the same disease and applying the same primary outcome measures. The exception to this rule may be the response to Janus-kinase-inhibitors, which seem to work 10 % better in all trials (JAK-bonus) This article provides a potential explanation for this remarkable phenomenon, including an explanation for the JAK-bonus. It seems as if JAK-inhibitors exert some inflammation-independent effects on pain, fatigue and wellbeing, and that drug treatment of rheumatic diseases is more than the inhibition of inflammation alone.
Authors 3
-
Robert Landewé corresponding
Amsterdam University Medical Centers · Zuyderland Medisch Centrum
Affiliation as printed
Department of Rheumatology & Clinical immunology, Amsterdam University Medical Center, Amsterdam, the kingdom of the Netherlands; Department of Rheumatology, Zuyderland Medical center, Heerlen, the kingdom of the Netherlands. Electronic address: landewe@rlandewe.nl
Department of Rheumatology & Clinical immunology, Amsterdam University Medical Center, Amsterdam, the Netherlands
Department of Rheumatology, Zuyderland Medical center, Heerlen, the Netherlands
-
Universidade Nova de Lisboa · Leiden University Medical Center
Affiliation as printed
Department of Rheumatology, Leiden University medical Center, Leiden, the kingdom of the Netherlands; NOVA Medical School, Universidade Nova de Lisboa, Portugal
Department of Rheumatology, Leiden University medical Center, Leiden, the Netherlands
NOVA Medical School, Universidade Nova de Lisboa, Portugal
-
Leiden University Medical Center
Affiliation as printed
Department of Rheumatology, Leiden University medical Center, Leiden, the kingdom of the Netherlands
Department of Rheumatology, Leiden University medical Center, Leiden, the Netherlands
Cited by 3 stored of 3
3 results
No patents citing this paper on Lens.org (checked 2026-10-11).